EUVIMEDEUVIMED entdecken
Crossref

ADME, Toxicity, Molecular Docking, Molecular Dynamics, Glucokinase activation, DPP‐IV, α‐amylase, and α‐glucosidase Inhibition Assays of Mangiferin and Friedelin for Antidiabetic Potential

Ravikiran Maheshrao Suryawanshi, Rupali Bhalchandra Shimpi, V Muralidharan, Lalita Shashikant Nemade, Simhachalam Gurugubelli, Shahajan Baig, Sunayana Rahul Vikhe, Sachin A Dhawale, Mohammad Rakib Mortuza, Sherouk Hussein Sweilam, Falak A Siddiqui, Sharuk L Khan und 3 weitere

Chemistry & Biodiversity · 2025-05 · 22 (5)

DOI: 10.1002/cbdv.202402738 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 13.01.2025. Verfasst von Ravikiran Maheshrao Suryawanshi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Industrial Pharmacy and Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India. Hauptthemen laut MEDLINE: Xanthones, Hypoglycemic Agents, alpha-Amylases, Glycoside Hydrolase Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: Large Research Group Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Today the alarming situation of diabetes seeks innovative antidiabetic medications, especially those derived from natural sources, as natural substances are safer than manufactured pharmaceuticals. Therefore, this study investigated the inhibitory properties of mangiferin and friedelin against glucokinase (GK), dipeptidyl peptidase‐IV (DPP‐IV), α‐amylase, and α‐glucosidase using computational methods, in vitro enzyme assays, and in‐depth ADMET analysis. The study utilized a computer‐aided drug design approach to assess the potential therapeutic properties of mangiferin and friedelin as Type 2 diabetes mellitus (T2DM) therapeutic agents. Molecular docking studies’ outcomes encouraged the evaluation of both compounds in in vitro enzymatic assays. The docking study results were validated with the help of molecular dynamics simulation. Mangiferin and friedelin showed that they activated GK 20% and 5% more than the basal activity of the enzyme, respectively. In the DPP‐IV enzyme assay, mangiferin and friedelin demonstrated IC 50 values (74.93 ± 0.71 and 110.64 ± 0.21 µg/mL, respectively) comparable with the reference compound sitagliptin. Moreover, mangiferin and friedelin showed IC 50 comparable to acarbose against α‐amylase (9.72 ± 0.15, 11.84 ± 0.06, and 10.19 ± 0.05 mg/mL, respectively). In the α‐glucosidase enzyme assay, mangiferin, friedelin, and acarbose displayed 11.72 ± 0.10, 14.34 ± 0.02, and 9.14 ± 0.06 mg/mL of IC 50 values, respectively. The compounds showed promising in silico ADMET and drug‐likeness properties, with potential binding affinities with all enzymes. In vitro enzymatic assays showed mangiferin and friedelin activated GK 20% and 5% more than basal activity, with IC 50 values comparable to acarbose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

XanthonesHypoglycemic Agentsalpha-AmylasesGlycoside Hydrolase InhibitorsTriterpenesDipeptidyl-Peptidase IV InhibitorsMolecular Docking Simulationalpha-GlucosidasesMolecular Dynamics SimulationDipeptidyl Peptidase 4HumansGlucokinaseStructure-Activity RelationshipMolecular StructureDose-Response Relationship, DrugDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

friedelinglucokinasein vitro enzymatic assaymangiferinα‐amylaseα‐glucosidase

Substanzen

XanthonesmangiferinHypoglycemic Agentsalpha-Glucosidasesalpha-AmylasesDipeptidyl Peptidase 4Glycoside Hydrolase InhibitorsGlucokinaseTriterpenesDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Department of Industrial Pharmacy and Quality Assurance, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
  • Department of Pharmacognosy, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
  • Department of Pharmaceutical Chemistry, Vishnu Institute of Pharmaceutical Education and Research, Hyderabad, India.
  • Department of Pharmaceutics, Govindrao Nikam College of Pharmacy, Sawarde, Maharashtra, India.
  • Internal Medicine Physician, Memorial Hospital, Gulfport, Mississippi, USA.
  • Department of Pharmacology, Government College of Pharmacy, Osmanpura, Chhatrapati Sambhaji Nagar, Maharashtra, India.

ORCID-Profile: Md Zamshed Alam Begh

Förderung

  • Large Research Group Project

Zitieren

APA

Suryawanshi, R. M., Shimpi, R. B., Muralidharan, V., Nemade, L. S., Gurugubelli, S., Baig, S., Vikhe, S. R., Dhawale, S. A., Mortuza, M. R., Sweilam, S. H., Siddiqui, F. A., Khan, S. L., Tutone, M., Ahmad, I., & Begh, M. Z. A. (2025). ADME, Toxicity, Molecular Docking, Molecular Dynamics, Glucokinase activation, DPP‐IV, α‐amylase, and α‐glucosidase Inhibition Assays of Mangiferin and Friedelin for Antidiabetic Potential. Chemistry & Biodiversity, 22(5). https://doi.org/10.1002/cbdv.202402738

Vancouver

Suryawanshi RM, Shimpi RB, Muralidharan V, Nemade LS, Gurugubelli S, Baig S, et al. ADME, Toxicity, Molecular Docking, Molecular Dynamics, Glucokinase activation, DPP‐IV, α‐amylase, and α‐glucosidase Inhibition Assays of Mangiferin and Friedelin for Antidiabetic Potential. Chemistry & Biodiversity. 2025;22(5). doi:10.1002/cbdv.202402738

BibTeX
@article{Suryawanshi2025,
  author = {Suryawanshi, Ravikiran Maheshrao and Shimpi, Rupali Bhalchandra and Muralidharan, V and Nemade, Lalita Shashikant and Gurugubelli, Simhachalam and Baig, Shahajan and Vikhe, Sunayana Rahul and Dhawale, Sachin A and Mortuza, Mohammad Rakib and Sweilam, Sherouk Hussein and Siddiqui, Falak A and Khan, Sharuk L and Tutone, Marco and Ahmad, Irfan and Begh, Md Zamshed Alam},
  title = {ADME, Toxicity, Molecular Docking, Molecular Dynamics, Glucokinase activation, DPP‐IV, α‐amylase, and α‐glucosidase Inhibition Assays of Mangiferin and Friedelin for Antidiabetic Potential},
  journal = {Chemistry & Biodiversity},
  year = {2025},
  volume = {22},
  number = {5},
  doi = {10.1002/cbdv.202402738}
}
Kostenlos starten →